louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06951984: Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease
Official title: Hydroxyephedrine PET/CT in Sympathetic Nervous System Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sympathetic Nervous System Diseases
Sympathetic Nervous Structure Injury
Sympathetic Nerve Injury
Keywords: PET/CT
MRI
Hydroxyephedrine
Lead sponsor: Tianjin Medical University
Sponsor class: OTHER
Collaborators: name: Tianjin Medical University General Hospital
First posted: 2025-04-30
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Brief summary: To evaluate the potential usefulness of 11C/18F-HED positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Detailed description: Subjects with various sympathetic nerves-related disease patients underwent 11C/18F-HED PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 11C/18F-HED PET/CT were calculated.

Eligibility criteria: Inclusion Criteria:

* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcomes:
measure: Standardized uptake value (SUV)
timeFrame: 30 days
Secondary outcomes:
measure: Diagnostic efficacy
timeFrame: 30 days
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT02160184: Nocturnal Insulin-Glucose in Hospital: Tight Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes
Lead sponsor: Corporacion Parc Tauli
Sponsor class: OTHER
First posted: 2014-06-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to assess the efficacy and safety of a closed-loop system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS) in patients with type 1 diabetes for controlling the nocturnal and post-breakfast periods. Intervention will be to apply the automated closed-loop system by administering a subcutaneous insulin microbolus every 5 minutes depending on reading from a continuous glucose measurement (CGM) system.


Eligibility criteria: Inclusion Criteria:

* Type 1 Diabetes
* Diabetes duration \> 3 years
* Continuous Subcutaneous Insulin Infusion (CSII) treatment for more than 1 year
* A1c 6-9%
* No ketoacidosis during the previous 12 months
* Glomerular Filtration Rate (GFR) \> 60 ml/kg/min m2
* Willingness of participate and signed and dated written informed consent in accordance with Good Clinical Practice

Exclusion Criteria:

* Gastroparesis
* Hypoglycemia unawareness
* Uncorrected visual impairment
* Deafness
* BMI\> 35 kg/m2

Primary outcomes:
measure: Percentage of time in target range (3.9-8.0 mmol/l) YSI glucose during the in clinic overnight visit.
timeFrame: During the closed-loop period for each patient: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Parc Tauli University Hospital
state: Barcelona
Study officials:
affiliation: Parc Tauli University Hospital
name: Mercedes Rigla, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02877784: Screening in Oculopharyngeal Muscular Dystrophy
Official title: Determination of Accurate Screening Tools for Dysphagia in Oculopharyngeal Muscular Dystrophy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oculopharyngeal Muscular Dystrophy
Keywords: screening
OPMD
dysphagia
dysarthria
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2016-08-24
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The sample population will consist of individuals with a diagnosis of oculopharyngeal muscular dystrophy.

Brief summary: Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathic disease that results in progressive degeneration of the oral and pharyngeal muscular, resulting in severe dysphagia and dysarthria. OPMD is considered a rare disease; therefore, limited research is available on the natural progression of the disease or the utility of biomarkers to identify swallowing impairment. The aim of this study is:

1. To identify accurate, reliable and non-invasive clinical markers of swallowing impairment
2. To determine the discriminate ability of these markers to identify impairments in swallow safety and swallowing efficiency.

Detailed description: Participants will be recruited from the Neurology clinic at the University of Florida. The single evaluation will occur in the PIs research laboratory at the University of Florida, Gainesville, Florida.

Eligibility criteria: Inclusion Criteria:

* diagnosis of oculopharyngeal muscular dystrophy
* no allergies to barium or capsaicin,
* no tracheotomy or mechanical ventilation
* no significant concurrent respiratory disease (e.g., COPD).

Exclusion Criteria:

* Pregnant Women

Primary outcomes:
measure: Dynamic Imaging Grade of Swallowing Toxicity
timeFrame: Baseline
Secondary outcomes:
measure: Dietary intake as confirmed by Functional Oral Intake Scale (FOIS)
timeFrame: Baseline
measure: Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10)
timeFrame: Baseline
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Emily Plowman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05515484: Improvement of Lung and Thoracic Compliance in ARDS Patients in Prone Position by Using Inflatable Air Bag
Official title: Improvement of Lung and Thoracic Compliance in ARDS Patients in Prone Position by Using Inflatable Air Bag
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: ARDS
Prone Position
Mechanical Ventilation
Airbag
Keywords: ARDS
prone position
mechanical ventilation
airbag
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2022-08-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ARDS is frequent in ICU and may lead to many complications and to death. Prone position is widely used in ADRS patients and demonstrated to decrease mortality. Regarding the chest wall compliance data are missing but the theorical response is that this compliance is decreased in a prone position mainly due to anterior chest and abdomen compression in this position which are more compliant that dorsal part of the body. As well prone position could be associated with complications as pressure ulcers. Because prone position is associated with complications, air bag were developped to decrease pressure on the chest and abdomen and to decrease pressure ulcers. Then, trying to improve chest compliance in prone position and reducing the risk of pressures ulcers could be a challenge with this system in comparison with standard care.


Eligibility criteria: Inclusion Criteria:

* patients with ARDS under mechanical ventilation with P/F ratio\<150
* Age \>18 y/o
* Admitted in the medical ICU of Amiens under mechanical ventilation sedated,
* With signed informed consent (patient or relative if patient is not conscious)

Exclusion Criteria:

* patients not eligible for a prone position
* Patients with tracheostomy

Primary outcomes:
measure: variation of Lung compliance between both groups
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
References:
Clinical trial NCT05350384: An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy
Official title: An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy: Presentation of a Unique Case
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Purtscher Retinopathy
Pancreatic Cancer
Lead sponsor: University of Catania
Sponsor class: OTHER
First posted: 2022-04-28
Enrollment: 1
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: No population, only one patient

Brief summary: AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY

Detailed description: Purtscher's retinopathy may cause sudden loss of vision of varying severity, secondary to head or chest injury. Its pathophysiology is unclear. Purtscher's-like retinopathy has more attenuated clinical and objective features and can be associated with many non-neoplastic pathologies.

Otherwise, an association of this kind of retinopathy with malignancies has been described once in the Literature (multiple myeloma). We present a case report on a unique association between pancreatic cancer and Purtscher-type retinopathy.

Eligibility criteria: Inclusion Criteria: NONE -

Exclusion Criteria: NONE

-

Primary outcomes:
measure: funduscopic examination
timeFrame: at the onset of symptoms
Secondary outcomes:
measure: abdominal CT-scan
timeFrame: at the onset of symptoms
Other outcomes:
measure: Unusual association between Purtscher-like retinopathy and a malignant disease (pancreatic cancer)
timeFrame: at the diagnosis
measure: Therapy
timeFrame: after 1 month from diagnosis
Locations:
city: Catania
country: Italy
facility: Eva Intagliata
Study officials:
References:
Clinical trial NCT05186584: Effects of Maitland's Antero-Posterior Versus Lateral Mobilizations on Cardiovascular Responses
Official title: Effects of Maitland's Antero-posterior Versus Lateral Mobilizations on Cardiovascular Responses in Non-Specific Chronic Neck Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neck Pain
Keywords: Maitland mobilization
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 62
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be a randomized control trial and will be conducted in Polyclinic Hospital Islamabad \& Rawal Dental and General Hospital Rawalpindi. A sample of 62 participants will be taken. Patients will be divided into two equal groups of 31 participants in each group, group Randomization will be done through flip coin method. Patients in group A will receive Maitland's antero-posterior Mobilization, while Patients in group B will receive Maitland's lateral mobilizations. 4 sessions of treatment will be given for 2 weeks with interval of 3 days, 4 days and 7 days between 1st \& 2nd session, 2nd \& 3rd session and 3rd \& 4th session, respectively. The outcome measures will be OMRON Automatic Blood Pressure Monitor, Numeric pain rating scale(NPRS) and Global Rating of Change questionare will be measured at baseline and at the end of 4th session. Data will be analyzed by SPSS 25.


Eligibility criteria: Inclusion Criteria:

* Participants falling in this category would be recruited into the study.
* Age 25 to 55 years
* Pain in neck with no known cause for \> 3 months
* Resting systolic blood pressure between 90 to 139 mmHg
* resting diastolic blood pressure between 60 to 88 mmHg
* resting heart rate between 60 to 100 beats/min
* no prior exposure to antero-posterior and lateral mobilizations

Exclusion Criteria:

* Participants falling in this category would be excluded from the study.
* age \<25 and \>55
* current smokers
* history of fainting spells, diabetes mellitus, spinal surgery and whiplash injury( in last 6 months)
* taking medications for blood thinning, diabetes mellitus
* having neurologic or cardiovascular disease, radiating pain, cervicogenic headaches
* movement coordination impairment
* athletes
* unable to read and write

Primary outcomes:
measure: OMRON Automatic Blood Pressure Monitor
timeFrame: 2 Weeks
measure: OMRON Automatic heart rate Monitor
timeFrame: 2 Weeks
measure: Numeric Pain Rating Scale (NPRS)
timeFrame: 2 Weeks
measure: Global Rating of Change (GROC)
timeFrame: 2 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Rawal General Hospital Rawalpindi
state: Punjab
Study officials:
affiliation: Riphah International University
name: Waqar Ahmed Awan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00522184: Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study
Official title: Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rheumatoid Arthritis
Keywords: intra-articular injection
acute synovitis
etanercept
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
Collaborators: name: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: 2007-08-29
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intra-articular injection of etanercept in patient suffering from rheumatoid arthritis: a double-blind randomized study for evaluation of efficacy and safety of etanercept versus intra-articular steroid injection in acute synovitis (knee,wrist,ankle,elbow)


Eligibility criteria: Inclusion Criteria:

* must be able to understand the information about the study
* diagnosis of rheumatoid arthritis for 6 month at least
* suffering for 2 weeks at least
* with evaluation of pain over 4/10
* with stable DMARDs treatment for three month at least

Exclusion Criteria:

* infection or surgery on the target joint
* treated with infliximab,adalimumab or anakinra

Primary outcomes:
measure: Pain
timeFrame: every month during six month
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: Rheumatology department, Hopital Archet I
Study officials:
affiliation: Rheumatology department, Nice
name: Christian H ROUX
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02873884: Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)
Official title: Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Psychotic Disorders
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2016-08-22
Enrollment: 30
Sex: ALL
Minimum age (years): 16
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: First episode psychosis patients

Brief summary: The first aim of this study is to test the effect of the case management on the evolution of therapeutic alliance in patients with first episode psychosis in comparison with traditional nursing. The second aim is to test the effect of case management on nurses' well-being in comparison with traditional nursing. The third objective aims to show if therapeutic alliance is associated with insight in patients and with clinical and demographic data.


Eligibility criteria: Inclusion Criteria:

* Age between 16 and 30 years
* First episode psychosis diagnosis according to DSM-5 criteria

Exclusion Criteria:

* Lees of 16 years or more than 30 years
* Not fulfilling DSM-5 criteria for first episode psychosis
* Any treatment with the psychologist or the psychiatrist of the team

Primary outcomes:
measure: Work alliance inventory
timeFrame: 6 months
Secondary outcomes:
measure: Birchwood insight scale
timeFrame: 6 months
measure: Scale to assess Unawareness of Mental Disorder
timeFrame: 6 months
measure: Well-being at work scale
timeFrame: 6 months
Other outcomes:
Locations:
city: Caen
country: France
facility: CHU de Caen
Study officials:
References:
Clinical trial NCT02479984: Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer
Official title: A Prospective Study Investigating the Role of Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pancreatic Cancer
Keywords: staging laparoscopy
pancreatic cancer
biliary cancer
Lead sponsor: National Cancer Center, Korea
Sponsor class: OTHER_GOV
First posted: 2015-06-24
Enrollment: 193
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the role of routine Staging Laparoscopy in patients with potentially resectable pancreatobiliary cancer.

Detailed description: To evaluate the role of routine staging laparoscopy in patients with potentially resectable pancreatobiliary cancer. All analyses are performed using SAS version 9.1.3 for Windows (SAS institute, Cary, NC). Clinical and pathological variables will be analyzed using the χ2 test (or Fisher's exact test) and the Student's t test, depending on the normality of the distribution. P-values of \< 0.05 are considering statistically significant.

Eligibility criteria: Inclusion Criteria:

1. Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT)
2. No evidence of distant metastasis
3. aged 15-80 year old
4. performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
5. adequate organ functions defined as indicated below

   1. WBC 3000 \~ 12 000/mm3
   2. \> Hb 8.0 g/dl
   3. \> Plt 100 000/mm3
   4. \< Cr 1.2 mg/dl
   5. \> Ccr 60 ml/min/body

Exclusion Criteria:

1. cystic neoplasm, neuroendocrine tumors
2. pregnant or breast-feeding women
3. previous upper abdominal surgery except laparoscopic cholecystectomy 4.Serious illness in medical condition

   1. unstable angina or myocardial infarction within 6 months of the trial
   2. unstable hypertension
   3. congestive heart failure
   4. severe respiratory disease requiring continuous oxygen therapy
   5. liver failure
   6. systemic administration of corticosteroids
   7. severe mental disorder

Primary outcomes:
measure: Probability of diagnosis of metastasis (frequency)
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Goyang
country: Korea, Republic of
facility: National Cancer Center
state: Gyeonggi
Study officials:
affiliation: National Cancer Center, Korea
name: Sang Jae Park, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04844684: Evaluation of Cortisol and Bile Acids Metabolism in Obese Patients
Official title: Link Between the Metabolism of Cortisol and Bile Acids in Obese Patients Before and After Bariatric Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity
Keywords: Cortisol
Bile acids
Obesity
Bariatric surgery
Insulin resistance
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2021-04-14
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted for bariatric surgery in the department of endocrine surgery at Lille University Hospital

Brief summary: Bariatric surgery is currently the most efficient treatment for obesity. The sustained weight loss and metabolic improvement seen following Roux-en-Y gastric bypass (RYGB), is explained partly by modifications in hormones including bile acids (BA). After RYGB, an increased total BA pool and a reduction in hepatic cortisol exposure is observed. Hydroxysteroid 11-β dehydrogenase 1 (HSD11B1), steroid 5α-reductases (SRD5A), and steroid 5β-reductases, AKR1D1 (also a BA metabolizing enzyme), are three enzymes involved in the metabolism of cortisol in the liver and are known to participate in metabolic syndrome. Their activity has been shown to be decreased after RYGB. Interestingly, the mechanisms explaining the modification of hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown. In view of the few data suggesting a link between cortisol metabolism and bile acids, this work aim to study and characterize this link in a context of RYBP


Eligibility criteria: Inclusion Criteria:

* Non-menopausal women
* BMI between 35 and 50 kg/m² included
* Social insured
* Ability to give consent

Exclusion Criteria:

* moderate and severe kidney insufficiency
* hepatic insufficiency
* known gallbladder lithiasis
* history of cholecystectomy or cholecystectomy planned during the gastric bypass
* history of bariatric surgery except gastric band and gastric balloon
* history of type 1
* treatment interfering with the cortisol metabolism: taking oral or inhaled glucocorticoids within the last 6 months
* treatment by BA as ursodeoxycholic acid, bile acids sequester, statin, fibrate stopped less than 4 weeks ago

Primary outcomes:
measure: Correlation between the variations of urinary cortisol metabolites and plasmatic total BA level before and after RYGB
timeFrame: At 1 year
Secondary outcomes:
measure: Urinary cortisol metabolite profile modification
timeFrame: At 1 month after RYGP, at 1 year after RYGP
measure: Urinary and plasmatic BA profile modification
timeFrame: At 1 month after RYGP, at 1 year after RYGP
measure: Correlation between the variations of cortisol metabolites and the variations of metabolic parameters 1 year after gastric bypass
timeFrame: at 1 year
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Lille
name: Stéphanie ESPIARD, MD
role: PRINCIPAL_INVESTIGATOR
References: